CO2024000631A2 - Composiciones, métodos y sistemas para la administración de fármacos en aerosol - Google Patents
Composiciones, métodos y sistemas para la administración de fármacos en aerosolInfo
- Publication number
- CO2024000631A2 CO2024000631A2 CONC2024/0000631A CO2024000631A CO2024000631A2 CO 2024000631 A2 CO2024000631 A2 CO 2024000631A2 CO 2024000631 A CO2024000631 A CO 2024000631A CO 2024000631 A2 CO2024000631 A2 CO 2024000631A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- systems
- methods
- drug delivery
- acting
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000443 aerosol Substances 0.000 title 1
- 238000012377 drug delivery Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 abstract 2
- 229940125390 short-acting beta agonist Drugs 0.000 abstract 2
- CDOOAUSHHFGWSA-OWOJBTEDSA-N (e)-1,3,3,3-tetrafluoroprop-1-ene Chemical compound F\C=C\C(F)(F)F CDOOAUSHHFGWSA-OWOJBTEDSA-N 0.000 abstract 1
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 abstract 1
- 239000003470 adrenal cortex hormone Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 abstract 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 abstract 1
- 229940125389 long-acting beta agonist Drugs 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220362P | 2021-07-09 | 2021-07-09 | |
| US202163282356P | 2021-11-23 | 2021-11-23 | |
| PCT/US2022/036542 WO2023283438A1 (en) | 2021-07-09 | 2022-07-08 | Compositions, methods and systems for aerosol drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024000631A2 true CO2024000631A2 (es) | 2024-02-15 |
Family
ID=82748203
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0000631A CO2024000631A2 (es) | 2021-07-09 | 2024-01-25 | Composiciones, métodos y sistemas para la administración de fármacos en aerosol |
| CONC2024/0000742A CO2024000742A2 (es) | 2021-07-09 | 2024-01-26 | Composiciones, métodos y sistemas para la administración de fármacos en aerosol |
| CONC2024/0000748A CO2024000748A2 (es) | 2021-07-09 | 2024-01-26 | Composiciones, métodos y sistemas para la administración de fármacos en aerosol |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0000742A CO2024000742A2 (es) | 2021-07-09 | 2024-01-26 | Composiciones, métodos y sistemas para la administración de fármacos en aerosol |
| CONC2024/0000748A CO2024000748A2 (es) | 2021-07-09 | 2024-01-26 | Composiciones, métodos y sistemas para la administración de fármacos en aerosol |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20240252440A1 (https=) |
| EP (6) | EP4393478A3 (https=) |
| JP (3) | JP2024525555A (https=) |
| KR (3) | KR20240042436A (https=) |
| AU (3) | AU2022305962A1 (https=) |
| CA (3) | CA3226557A1 (https=) |
| CL (3) | CL2024000041A1 (https=) |
| CO (3) | CO2024000631A2 (https=) |
| CR (3) | CR20240064A (https=) |
| DK (3) | DK4197528T3 (https=) |
| DO (3) | DOP2024000004A (https=) |
| EC (1) | ECSP24011022A (https=) |
| ES (3) | ES2983201T3 (https=) |
| FI (3) | FI4175620T3 (https=) |
| HR (3) | HRP20240716T1 (https=) |
| HU (3) | HUE067283T2 (https=) |
| IL (3) | IL309888A (https=) |
| LT (3) | LT4175619T (https=) |
| MA (3) | MA60224B1 (https=) |
| MX (3) | MX2024000465A (https=) |
| PE (3) | PE20240807A1 (https=) |
| PL (3) | PL4197528T3 (https=) |
| PT (3) | PT4175619T (https=) |
| RS (3) | RS65598B1 (https=) |
| SI (3) | SI4175620T1 (https=) |
| SM (3) | SMT202400370T1 (https=) |
| TW (3) | TW202317079A (https=) |
| WO (3) | WO2023283439A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250345292A1 (en) * | 2022-04-28 | 2025-11-13 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
| CN116270464B (zh) * | 2023-03-01 | 2025-09-30 | 深圳市贝美药业有限公司 | 一种克立硼罗气雾剂及其制备方法 |
| FR3150798B1 (fr) | 2023-07-07 | 2025-11-21 | Aptar France Sas | Dispositif de distribution de produit fluide |
| WO2025179277A1 (en) | 2024-02-23 | 2025-08-28 | Zelicovich Marcelo Lazaro | Aerosol delivery system with enhanced air suspension |
| TW202600144A (zh) * | 2024-02-23 | 2026-01-01 | 瑞典商阿斯特捷利康公司 | Copd之三重組合療法 |
| WO2026006658A1 (en) * | 2024-06-27 | 2026-01-02 | Lupin Inc. | Stable pharmaceutical compositions for pressurized metered dose inhalers |
| US20260007598A1 (en) * | 2024-07-05 | 2026-01-08 | Honeywell International Inc. | Compositions, devices and methods for respritory delivery of active pharmaceutical ingredients |
| GB202410910D0 (en) * | 2024-07-25 | 2024-09-11 | Bespak Europe Ltd | Method of filling a pressurised dispensing container and filled pressurised dispensing container |
| US12496272B1 (en) | 2024-07-31 | 2025-12-16 | Amphastar Pharmaceuticals, Inc. | Stable epinephrine suspension formulation for inhalation with HFO propellant |
| US12383516B1 (en) | 2025-01-06 | 2025-08-12 | Amphastar Pharmaceuticals, Inc. | Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US37872A (en) | 1863-03-10 | Improved mast-hoop | ||
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| SE378109B (https=) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US4187301A (en) | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
| BE887518A (fr) | 1980-02-15 | 1981-08-13 | Glaxo Group Ltd | Cartothioates d'androstanes |
| CY1359A (en) | 1981-02-02 | 1987-08-07 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| US5707634A (en) | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| SE9404080L (sv) | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| ATE287703T1 (de) | 1995-04-14 | 2005-02-15 | Nektar Therapeutics | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| US5886200A (en) | 1996-07-01 | 1999-03-23 | Schering Corporation | Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| NZ500555A (en) | 1999-08-02 | 2000-11-24 | Hovione Int Ltd | Process for the preparation of mometasone furoate |
| NZ518401A (en) | 1999-10-29 | 2004-01-30 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
| PT1280520E (pt) | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| SI3170880T1 (sl) | 2002-10-25 | 2020-07-31 | Honeywell International Inc. | Uporaba sestavkov, ki kot hladilni sestavek vsebujejo HFO-1234ZE ali HFO-1234YF |
| US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| ES2335498T3 (es) | 2003-03-10 | 2010-03-29 | Nycomed Gmbh | Nuevo proceso para la preparacion de reflumilast. |
| KR20060015316A (ko) | 2003-05-28 | 2006-02-16 | 넥타르 테라퓨틱스 | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법 |
| US9308199B2 (en) | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
| AU2006272438B2 (en) | 2005-07-15 | 2011-08-04 | Map Pharmaceuticals, Inc. | Method of particle formation |
| CN100560598C (zh) | 2005-07-26 | 2009-11-18 | 上海奥锐特国际贸易有限公司 | 氟替卡松丙酸酯的合成方法 |
| CA2669924A1 (en) * | 2006-11-20 | 2008-05-29 | Cipla Limited | An aerosol device |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| PL3111927T3 (pl) | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy |
| SG181870A1 (en) * | 2009-12-23 | 2012-07-30 | Chiesi Farma Spa | Aerosol formulation for copd |
| RU2013155903A (ru) * | 2011-05-17 | 2015-06-27 | Перл Терапьютикс, Инк. | Композиции, способы и устройства для респираторной доставки двух или более активных средств |
| CN104080770A (zh) | 2011-11-09 | 2014-10-01 | 迈兰实验室有限公司 | 用于制备罗氟司特的改进方法 |
| CN107596518B (zh) * | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| WO2014060464A1 (en) | 2012-10-17 | 2014-04-24 | Interquim, S.A. | Process for preparing roflumilast |
| HUE052275T2 (hu) * | 2013-01-28 | 2021-04-28 | Incozen Therapeutics Pvt Ltd | Eljárások autoimmun, légzõszervi és gyulladásos rendellenességek kezelésére roflumilaszt N-oxid inhalálásával |
| US20150150787A1 (en) * | 2013-05-22 | 2015-06-04 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of three or more active agents |
| ES2970740T3 (es) | 2017-10-09 | 2024-05-30 | Pearl Therapeutics Inc | Unidad de administración de aerosol |
-
2022
- 2022-07-08 CA CA3226557A patent/CA3226557A1/en active Pending
- 2022-07-08 KR KR1020247004328A patent/KR20240042436A/ko active Pending
- 2022-07-08 EP EP24161253.0A patent/EP4393478A3/en active Pending
- 2022-07-08 MA MA60224A patent/MA60224B1/fr unknown
- 2022-07-08 PL PL23155432.0T patent/PL4197528T3/pl unknown
- 2022-07-08 SM SM20240370T patent/SMT202400370T1/it unknown
- 2022-07-08 MX MX2024000465A patent/MX2024000465A/es unknown
- 2022-07-08 KR KR1020247004330A patent/KR20240042438A/ko active Pending
- 2022-07-08 TW TW111125752A patent/TW202317079A/zh unknown
- 2022-07-08 US US18/577,168 patent/US20240252440A1/en active Pending
- 2022-07-08 DK DK23155432.0T patent/DK4197528T3/da active
- 2022-07-08 HU HUE22751897A patent/HUE067283T2/hu unknown
- 2022-07-08 US US17/861,072 patent/US20230026203A1/en not_active Abandoned
- 2022-07-08 CR CR20240064A patent/CR20240064A/es unknown
- 2022-07-08 SI SI202230039T patent/SI4175620T1/sl unknown
- 2022-07-08 MX MX2024000467A patent/MX2024000467A/es unknown
- 2022-07-08 LT LTEPPCT/US2022/036543T patent/LT4175619T/lt unknown
- 2022-07-08 WO PCT/US2022/036543 patent/WO2023283439A1/en not_active Ceased
- 2022-07-08 FI FIEP22751897.4T patent/FI4175620T3/fi active
- 2022-07-08 TW TW111125764A patent/TW202317080A/zh unknown
- 2022-07-08 US US18/577,176 patent/US20240252432A1/en active Pending
- 2022-07-08 WO PCT/US2022/036542 patent/WO2023283438A1/en not_active Ceased
- 2022-07-08 HU HUE23155432A patent/HUE067547T2/hu unknown
- 2022-07-08 TW TW111125791A patent/TW202317081A/zh unknown
- 2022-07-08 HU HUE22748656A patent/HUE067281T2/hu unknown
- 2022-07-08 WO PCT/US2022/036548 patent/WO2023283441A1/en not_active Ceased
- 2022-07-08 SI SI202230041T patent/SI4175619T1/sl unknown
- 2022-07-08 SM SM20240368T patent/SMT202400368T1/it unknown
- 2022-07-08 FI FIEP22748656.0T patent/FI4175619T3/fi active
- 2022-07-08 AU AU2022305962A patent/AU2022305962A1/en active Pending
- 2022-07-08 HR HRP20240716TT patent/HRP20240716T1/hr unknown
- 2022-07-08 LT LTEP23155432.0T patent/LT4197528T/lt unknown
- 2022-07-08 ES ES22751897T patent/ES2983201T3/es active Active
- 2022-07-08 EP EP24161189.6A patent/EP4393477A3/en active Pending
- 2022-07-08 RS RS20240630A patent/RS65598B1/sr unknown
- 2022-07-08 PL PL22751897.4T patent/PL4175620T3/pl unknown
- 2022-07-08 RS RS20240629A patent/RS65597B1/sr unknown
- 2022-07-08 HR HRP20240753TT patent/HRP20240753T1/hr unknown
- 2022-07-08 CR CR20240063A patent/CR20240063A/es unknown
- 2022-07-08 JP JP2024500203A patent/JP2024525555A/ja active Pending
- 2022-07-08 DK DK22748656.0T patent/DK4175619T3/da active
- 2022-07-08 SM SM20240312T patent/SMT202400312T1/it unknown
- 2022-07-08 PE PE2024000057A patent/PE20240807A1/es unknown
- 2022-07-08 EP EP22748658.6A patent/EP4366695A1/en active Pending
- 2022-07-08 ES ES22748656T patent/ES2981514T3/es active Active
- 2022-07-08 MA MA60223A patent/MA60223B1/fr unknown
- 2022-07-08 JP JP2024500250A patent/JP2024525567A/ja active Pending
- 2022-07-08 JP JP2024500201A patent/JP2024527348A/ja active Pending
- 2022-07-08 CA CA3226153A patent/CA3226153A1/en active Pending
- 2022-07-08 PT PT227486560T patent/PT4175619T/pt unknown
- 2022-07-08 MX MX2024000468A patent/MX2024000468A/es unknown
- 2022-07-08 HR HRP20240725TT patent/HRP20240725T1/hr unknown
- 2022-07-08 PE PE2024000056A patent/PE20241067A1/es unknown
- 2022-07-08 CR CR20240066A patent/CR20240066A/es unknown
- 2022-07-08 PE PE2024000058A patent/PE20240808A1/es unknown
- 2022-07-08 IL IL309888A patent/IL309888A/en unknown
- 2022-07-08 ES ES23155432T patent/ES2981709T3/es active Active
- 2022-07-08 IL IL309907A patent/IL309907A/en unknown
- 2022-07-08 AU AU2022306682A patent/AU2022306682A1/en active Pending
- 2022-07-08 IL IL309908A patent/IL309908A/en unknown
- 2022-07-08 PT PT227518974T patent/PT4175620T/pt unknown
- 2022-07-08 EP EP22748656.0A patent/EP4175619B1/en active Active
- 2022-07-08 FI FIEP23155432.0T patent/FI4197528T3/fi active
- 2022-07-08 AU AU2022308837A patent/AU2022308837A1/en active Pending
- 2022-07-08 PL PL22748656.0T patent/PL4175619T3/pl unknown
- 2022-07-08 DK DK22751897.4T patent/DK4175620T3/da active
- 2022-07-08 RS RS20240576A patent/RS65537B1/sr unknown
- 2022-07-08 KR KR1020247004329A patent/KR20240042437A/ko active Pending
- 2022-07-08 CA CA3226155A patent/CA3226155A1/en active Pending
- 2022-07-08 PT PT231554320T patent/PT4197528T/pt unknown
- 2022-07-08 EP EP22751897.4A patent/EP4175620B1/en active Active
- 2022-07-08 US US18/577,165 patent/US20240358662A1/en active Pending
- 2022-07-08 MA MA61888A patent/MA61888B1/fr unknown
- 2022-07-08 LT LTEPPCT/US2022/036542T patent/LT4175620T/lt unknown
- 2022-07-08 SI SI202230038T patent/SI4197528T1/sl unknown
- 2022-07-08 EP EP23155432.0A patent/EP4197528B1/en active Active
-
2024
- 2024-01-03 DO DO2024000004A patent/DOP2024000004A/es unknown
- 2024-01-04 DO DO2024000005A patent/DOP2024000005A/es unknown
- 2024-01-05 CL CL2024000041A patent/CL2024000041A1/es unknown
- 2024-01-05 DO DO2024000006A patent/DOP2024000006A/es unknown
- 2024-01-05 CL CL2024000039A patent/CL2024000039A1/es unknown
- 2024-01-05 CL CL2024000037A patent/CL2024000037A1/es unknown
- 2024-01-25 CO CONC2024/0000631A patent/CO2024000631A2/es unknown
- 2024-01-26 CO CONC2024/0000742A patent/CO2024000742A2/es unknown
- 2024-01-26 CO CONC2024/0000748A patent/CO2024000748A2/es unknown
- 2024-02-09 EC ECSENADI202411022A patent/ECSP24011022A/es unknown
- 2024-02-28 US US18/590,826 patent/US20240325298A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024000631A2 (es) | Composiciones, métodos y sistemas para la administración de fármacos en aerosol | |
| Husein‐ElAhmed et al. | Lichen planus: a comprehensive evidence‐based analysis of medical treatment | |
| Gessner et al. | Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (ARGON) | |
| AR038644A1 (es) | Formulaciones hfa de agonistas beta-2 de derivados de 2 (1h)-quinolinona de accion prolongada | |
| MX337126B (es) | Administracion respiratoria de agentes activos. | |
| Braunstein et al. | Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs: Braunstein, Hickey and Ekins | |
| Hayden | Newer influenza antivirals, biotherapeutics and combinations | |
| MX2013013440A (es) | Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos. | |
| DK1257254T3 (da) | Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom | |
| NO20083375L (no) | Farmasoytisk formulering for aerosoler, omfattende to eller aktive midler og minst et overflate aktivt middel | |
| AR038643A1 (es) | Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico | |
| Parumasivam et al. | In vitro evaluation of inhalable verapamil-rifapentine particles for tuberculosis therapy | |
| Javelot et al. | Towards a pharmacochemical hypothesis of the prophylaxis of SARS-CoV-2 by psychoactive substances | |
| AR126412A1 (es) | Composiciones, métodos y sistemas para la administración de fármacos en aerosol | |
| Chunhachaichana et al. | Development of nanodispersion-based sildenafil metered-dose inhalers stabilized by poloxamer 188: A potential candidate for the treatment of pulmonary arterial hypertension | |
| NO20074854L (no) | Farmasoytiske aerosolformuleringer for komprimerte, utmalte doseinhalatorer omfattende et sekvestreringsmiddel | |
| AR057745A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
| Jones et al. | Treatment of perennial rhinitis with flunisolide corticosteroid spray. | |
| Brown et al. | The possibility of short‐term hypothalamic‐pituitary‐adrenal axis suppression with high‐volume, high‐dose nasal mometasone irrigation in postsurgical patients with chronic rhinosinusitis | |
| Friedlander | Medical Management of Chronic Rhinosinusitis in Children and Adults | |
| Barnes | Novel mechanisms and new therapies for chronic obstructive pulmonary disease | |
| AR093601A1 (es) | Composiciones, metodos y sistemas para administracion respiratoria de dos o mas agentes activos | |
| UA109530C2 (uk) | Композиції, способи та системи для доставки респіраторним шляхом двох чи більше активних агентів | |
| Lyseng-Williamson | Formoterol/budesonide pressurized metered-dose inhaler: a guide to its use in chronic obstructive pulmonary disease | |
| ECSP13013082A (es) | Composiciones, métodos y sistemas para administración respiratoria de dos o más agentes activos |